Actively Recruiting
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Led by University of Alabama at Birmingham · Updated on 2026-04-13
50
Participants Needed
1
Research Sites
240 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with graft failure or delayed engraftment may benefit from a hematopoietic stem cell boost or an additional hematopoietic stem cell transplantation procedure. In such settings standard immune suppression strategies are avoided due to their myelosuppressive nature. Therefore those patients are at increased risk of graft versus host disease, and the infusion of a CD34 selected graft would reduce such a risk. The infusion of CD34 selected graft using CliniMACS plus is currently FDA FDA-approved indication for acute myeloid leukemia. However, the use of the Prodigy would streamline the processing, in terms of hands-off procedure, allowing to provision of this product to the patients without strains on the cell therapy lab team. This procedure has been demonstrated safe and effective in several single-center studies and is currently in advanced phase investigation in several studies for malignant and non-malignant conditions.
CONDITIONS
Official Title
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- AML in morphologic remission with intermediate/high-risk features or relapsed disease 1 or 2
- ALL in morphologic remission with high-risk features or relapsed disease 1 or 2
- Lymphoid malignancies in complete or partial remission (e.g., non-Hodgkin's lymphoma, prolymphocytic leukemia, CLL)
- Myelodysplastic syndromes with 10% or fewer blasts
- CML in morphologic remission after blast or accelerated phase
- Primary myelofibrosis with 10% or fewer blasts
- Morphologic remission defined as fewer than 5% blasts on bone marrow biopsy
- Negative test for donor-specific antibody within 28 days before starting conditioning, or adequate for standard desensitization protocol
You will not qualify if you...
- Non-compliant patients
- No appropriate caregivers identified
- Uncontrolled medical or psychiatric disorders that may prevent study participation (attending physician discretion)
- Known allergy to DMSO
- Pregnant or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294-3300
Actively Recruiting
Research Team
A
Antonio Di Stasi, M.D.
CONTACT
C
Chowdury Nazma
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here